Ethoxzolamide
FDA-approved product (tablet, oral), marketed as Cardrase, Ethamide.
- Registered studies
- 0
- Lab records
- 2
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLNo approved indication recorded
ChEMBL records no approved indication for Ethoxzolamide. Its therapeutic class is shown instead.
- Anti-infective classification
- Neither a WHO ATC code nor an FDA pharmacologic class was found for it, so whether it is already an antimicrobial is not established. It needs review and is not counted as a repurposing candidate.
Repurposing investigation
Ethoxzolamide reaches ≥40% AI-predicted activity against M. tuberculosis, but no WHO ATC code or FDA pharmacologic class says whether it is already an antimicrobial. It needs review, so it is not counted among the repurposing candidates.
AI-predicted activity
AI prediction · nothing measured- MRSA37.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli34.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae14.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis82.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
No evidence found
The registry was searched and no registered study names this medicine.
Experimental
- M. tuberculosis: measured active in 2 of 2 lab records
Show the 2 laboratory records, with sources
Loading records…
“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Ethoxzolamide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Pipecuronium BromideExisting use: Other quaternary ammonium compounds42.9% AI-predicted activityagainst K. pneumoniae5 registered studies
- Fosaprepitant DimeglumineExisting use: Cancer, Chemotherapy-induced nausea and vomiting, Nausea and 3 more42.9% AI-predicted activityagainst K. pneumoniae21 registered studies
- CabergolineExisting use: Hypothalamic neoplasm, Parkinson disease42.8% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Fondaparinux SodiumExisting use: Deep vein thrombosis, Intermediate coronary syndrome, Myocardial infarction and 3 more42.7% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Zavegepant HydrochlorideExisting use: Migraine disorder42.6% AI-predicted activityagainst K. pneumoniaeNo documented evidence found
- ApalutamideExisting use: Cancer, Metastatic prostate cancer, Neoplasm and 3 more42.0% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Vecuronium BromideExisting use: Other quaternary ammonium compounds42.0% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Lenacapavir SodiumExisting use: HIV infection, HIV-1 infection, Viral disease42.0% AI-predicted activityagainst K. pneumoniaeNo documented evidence found
- Lumateperone TosylateExisting use: Psychosis, Schizophrenia41.9% AI-predicted activityagainst K. pneumoniae6 registered studies
- RepotrectinibExisting use: Cancer, Neoplasm41.8% AI-predicted activityagainst K. pneumoniae17 registered studies
- MoxidectinExisting use: Helminthiasis, Onchocerciasis41.7% AI-predicted activityagainst K. pneumoniae25 registered studies
- PralsetinibExisting use: Cancer, Medullary thyroid gland carcinoma, Neoplasm and 1 more41.5% AI-predicted activityagainst K. pneumoniae19 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
No evidence found: the registry was searched and no registered study names this medicine.